Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

• Status: Approved for marketing
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• renal cell carcinoma that is not amendable to standard therapy with curative intent

Exclusion Criteria:

• current treatment in another therapeutic clinical trial